Kinase-targeted cancer therapies have made significant progress in clinical treatment, with many small-molecule kinase inhibitors approved for various cancers. Kinases, which transfer phosphate groups to proteins, are the second most targeted drug targets after G-protein-coupled receptors. Over 37 kinase inhibitors have been approved by the FDA for malignancies such as breast and lung cancer, and over 150 are in clinical trials. However, clinical efficacy is influenced by factors such as tumor genetics, microenvironment, drug resistance, and pharmacogenomics. Kinase inhibitors target specific pathways, reducing toxicity to non-cancerous cells and improving patient outcomes. Examples include imatinib and dasatinib, which have shown better results than conventional chemotherapy. These inhibitors have improved survival rates in myeloid leukemia and gastrointestinal stromal tumors. The FDA has approved numerous kinase inhibitors, including EGFR, ERBB2, VEGFRs, Kit, PDGFRs, ABL, SRC, and mTOR. Most inhibitors target the ATP-binding site, while some target allosteric sites. Recent advances in drug design, including structure-based methods and molecular docking, have improved inhibitor development. Over 10,000 kinase inhibitor patents have been filed in the US since 2001. Kinase-targeted antibodies, such as cetuximab and trastuzumab, have also shown efficacy in various cancers. Despite progress, challenges remain, including drug resistance, toxicity, and limited selectivity. Kinase inhibitors are crucial for cancer therapy, with over 28 approved inhibitors targeting one or multiple kinases. Recent developments include precision therapy based on tumor genomic data and the use of natural compounds as kinase inhibitors. Natural compounds such as resveratrol, quercetin, and curcumin have shown potential in inhibiting kinases involved in cancer. Challenges include resistance development and the need for more selective inhibitors. Overall, kinase-targeted therapies offer promising approaches for cancer treatment, but further research is needed to overcome existing limitations.Kinase-targeted cancer therapies have made significant progress in clinical treatment, with many small-molecule kinase inhibitors approved for various cancers. Kinases, which transfer phosphate groups to proteins, are the second most targeted drug targets after G-protein-coupled receptors. Over 37 kinase inhibitors have been approved by the FDA for malignancies such as breast and lung cancer, and over 150 are in clinical trials. However, clinical efficacy is influenced by factors such as tumor genetics, microenvironment, drug resistance, and pharmacogenomics. Kinase inhibitors target specific pathways, reducing toxicity to non-cancerous cells and improving patient outcomes. Examples include imatinib and dasatinib, which have shown better results than conventional chemotherapy. These inhibitors have improved survival rates in myeloid leukemia and gastrointestinal stromal tumors. The FDA has approved numerous kinase inhibitors, including EGFR, ERBB2, VEGFRs, Kit, PDGFRs, ABL, SRC, and mTOR. Most inhibitors target the ATP-binding site, while some target allosteric sites. Recent advances in drug design, including structure-based methods and molecular docking, have improved inhibitor development. Over 10,000 kinase inhibitor patents have been filed in the US since 2001. Kinase-targeted antibodies, such as cetuximab and trastuzumab, have also shown efficacy in various cancers. Despite progress, challenges remain, including drug resistance, toxicity, and limited selectivity. Kinase inhibitors are crucial for cancer therapy, with over 28 approved inhibitors targeting one or multiple kinases. Recent developments include precision therapy based on tumor genomic data and the use of natural compounds as kinase inhibitors. Natural compounds such as resveratrol, quercetin, and curcumin have shown potential in inhibiting kinases involved in cancer. Challenges include resistance development and the need for more selective inhibitors. Overall, kinase-targeted therapies offer promising approaches for cancer treatment, but further research is needed to overcome existing limitations.